BAXTER INTERNATIONAL INC acquired Claris Injectables Limited (Claris) for approximately $629 million total cash consideration, net of cash acquired, a transaction completed in July 2017, structured as all cash.
Claris Injectables Limited (Claris) operates in Generic injectable pharmaceuticals, is based in Ahmedabad, India, had revenue of about Contributed $57 million of net sales to Baxter in 2017 (partial year). Claris Injectables Limited, a wholly owned subsidiary of Claris Lifesciences Limited, is a generic injectable pharmaceuticals maker producing essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives and critical care products in bags, vials and ampoules.
Through the acquisition, Baxter added capabilities in the production of essential generic injectable medicines, expanding its hospital and pharmacy product portfolio.
Added a sterile generic-injectables manufacturing platform and product portfolio in a fast-growing hospital-pharmaceuticals segment. Integrated into Baxter's pharmaceuticals / hospital products business
On July 27, 2017, Baxter acquired 100 percent of Claris Injectables Limited (Claris), a wholly owned subsidiary of Claris Lifesciences Limited, for total cash consideration of approximately $629 million, net of cash acquired. Through the acquisition, Baxter added capabilities in production of essential generic injectable medicines, such as anesthesia and analgesics, renal, anti-infectives and critical care in a variety of presentations including bags, vials and ampoules.Baxter FY2017 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.